Newsmeme!
Discover News you didn't know existed
Immunosuppression
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial
Published February 10, 2010, 6:00 am, GlobeNewswire via Yahoo! Finance
PALO ALTO, Calif. -- StemCells, Inc. announced today that its proprietary HuCNS-SC® human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease , a myelination disorder that afflicts male children. The stem cells were administered yesterday at the University of California, San Francisco Children's Hospital by direct ...
Athersys Receives U.S. Patent Covering Adult Stem Cell Composition & Production
Published February 10, 2010, 3:30 am, GlobeNewswire via Yahoo! Finance
CLEVELAND -- Athersys, Inc. announced today that it has been granted U.S. patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions. Athersys also announced that it has been granted – and the opposition period has cleared – EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation ...
Lux Biosciences Files For LUVENIQ™ Approval In US And Europe For Noninfectious Uveitis
Published February 6, 2010, 12:48 am, Medical News Today
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye. Efficacy of LX211 in ...
Lux Biosciences seeks US and European marketing approval for LUVENIQ
Published February 4, 2010, 9:16 pm, News-Medical-Net
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |